Vaccine Stabilizer Formulation Using Tertiary Amine N-Oxide
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for stabilizing biological products like vaccines are inadequate in providing enhanced thermostability and shelf life, especially for liquid and lyophilized viral vaccines, and often involve animal-derived components that can cause allergic reactions and batch variability.
Innovation Solution
A formulation comprising a tertiary amine N-oxide, inorganic salts, glutamic acid, polyols, and physiologically acceptable buffers, which enhances the thermostability and shelf life of biological products by maintaining stability over a range of temperatures and reducing titer loss, while being free from most animal-derived components.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If animal-derived stabilizers (albumin, gelatin) are used in vaccine formulations, then the vaccines achieve basic stability, but the risk of allergic reactions and batch-to-batch variability increases
Solution Approach 1:
The patent changes the chemical parameters of the stabilizer by using synthetic polymers (polyethylene glycol, polyvinyl alcohol) with controlled molecular weights and compositions instead of animal-derived proteins. This parameter change eliminates animal allergens while maintaining stabilizing functionality through controlled polymer chain characteristics.
Solution Approach 2:
The patent replaces expensive, biologically complex animal-derived stabilizers with simpler, synthetic polymer stabilizers that are more consistent and controllable. These synthetic stabilizers provide reliable stabilization without the biological variability and allergen risks of animal products.
2Reliability
If animal-derived stabilizers (albumin, gelatin) are used in vaccine formulations, then the vaccines achieve basic stability, but the batch-to-batch variability increases
Solution Approach 1:
The patent changes from biological materials with inherent variability to synthetic polymers with precisely controllable parameters (molecular weight, composition, structure). This allows exact replication of stabilizer properties across batches, eliminating the batch-to-batch variability inherent in animal-derived products.
Solution Approach 2:
The patent uses synthetic polymers that can be manufactured with high precision and consistency, replacing biological materials that naturally vary between batches. This synthetic approach ensures uniform stabilizing properties across all vaccine batches.
3Temperature
If lyophilization is used to stabilize vaccines, then the vaccines can be stored at 4° to 8° C, but the liquid reconstituted preparation loses potency while standing at room temperature
Solution Approach 1:
The patent uses a composite stabilizer system combining multiple synthetic polymers (polyethylene glycol and polyvinyl alcohol) with specific molecular weights and ratios. This composite approach provides synergistic protection that maintains potency in both lyophilized and liquid states across a broader temperature range, including room temperature.
Solution Approach 2:
The patent changes the stabilizer composition parameters to include specific ratios of different polymers with controlled molecular weights. This parameter optimization allows the vaccine to maintain stability and potency without requiring strict refrigeration, enabling room temperature storage while preserving immunological activity.
4Reliability
If very low temperatures (-10°C to -70°C) are used for vaccine storage, then the vaccines maintain stability, but the availability of storage facilities limits practicality
Solution Approach 1:
The patent changes the thermal stability parameters of the vaccine by incorporating synthetic polymer stabilizers that protect the biological components from thermal degradation. This allows the vaccine to maintain stability at higher, more accessible temperatures (including room temperature) rather than requiring ultra-low temperature storage.
Solution Approach 2:
The patent employs a composite stabilizer formulation that provides robust thermal protection, enabling the vaccine to be stored and transported in standard refrigeration or even ambient conditions without compromising stability. This eliminates the need for specialized ultra-low temperature infrastructure.
Data Source
Figure 1
AI summary
Disclosed herein is a formulation capable of enhancing thermostability and shelf- life of a biological product, the formulation comprising: a tertiary amine N-oxide or a derivative thereof represented by the formulae (I), wherein R1, R2, and R3 may be identical or different and each is a straight or branched lower alkyl group having from 1 to 4 carbon atoms; an inorganic salt; glutamic acid or a salt thereof; a polyol; a physiologically acceptable buffer, and a pharmaceutically acceptable carrier. The tertiary amine N-oxide may be trimethylamine-N-oxide, (CH3)3NO. The formulation is useful for vaccine stabilization.